Abstract:Background: Type 1 diabetes is a polygenic disease that is influenced by environmental factors. A cure is not available, and patients depend on lifelong insulin injections. There is no clinical drug that can both promote the proliferation of islet beta cells and eliminate the immune attack of autoreactive T cells on beta cells. This study aimed to design a new bifunctional fusion polypeptide that is expected to have a good effect on type 1 diabetes.Methods: Our previous studies found that VP peptide, an immunomodulatory peptide that can eliminate inflammatory microenvironment, and EGLP-1, a structural analogue of GLP-1 that has the effect of protection of the pancreatic beta cells. So, we combined VP peptide and EGLP-1 to form a novel bifunctional peptide P30, hoping that VP may be an appropriate target as an immuno-modulatory arm, while GLP-1 analog may be suitable as a beta cell protective arm in combination therapy for T1D. The protective effect of each group on islets was determined by H&E and immunofluorescence, and the proportion of Treg/Th17 and Th2/Th1 cells were detected by flow cytometry.Findings: Our data demonstrate that P30 treatment significantly reduced the morbidity and mortality in NOD mice and alleviated pancreatitis symptoms. In addition, P30 has the function of enhancing immunoregulation involving increasing the ratio of Treg/Th17 cells and Th2/Th1 cells. Interpretation: These findings indicate that P30 represents a very promising strategy for prevention type 1 diabetes in mouse models of NOD.Funding: National Natural Science Foundation of China (Grant No. 81570696 and No. 31270985); Qing Lan Project; Program for Jiangsu Province Innovative Research Team; the Fundamental Research Funds for the Central Universities (2016ZPY010, 2632017PY06).Declaration of Interest: The authors declare that there is no duality of interest associated with this manuscript.Ethical Approval: All studies were approved by the Institutional Animal Care and Use Committee of China Pharmaceutical University (Nanjing, China).

Reversal of New-Onset Diabetes Through Modulating Inflammation and Stimulating Β-Cell Replication in Nonobese Diabetic Mice by a Dipeptidyl Peptidase IV Inhibitor

Successful β cells islet regeneration in streptozotocin-induced diabetic baboons using ultrasound-targeted microbubble gene therapy with cyclinD2/CDK4/GLP1.

Continuous stimulation of dual-function peptide PGLP-1-VP inhibits the morbidity and mortality of NOD mice through anti-inflammation and immunoregulation

Foxp3-expressing CD4+T Cells under the Control of IFN-γ Promoter Prevent Diabetes in NOD Mice

A Novel Dual-Function GLP-1 Analogue Prevents Type 1 Diabetes Onset in NOD Mice by Controlling the Balance of Treg/Th17 and Th2/Th1

Natural Killer Cells Modulate Overt Autoimmunity to Homeostasis in Nonobese Diabetic Mice after Anti-CD3 F(ab′)2 Antibody Treatment through Secreting Transforming Growth Factor-β

New DiaP277 analogue shifts DCs to tolerogenic, and modulates NF-Kβ1 to suppress autoreactive T lymphocytes in the type 1 diabetic mice.

Reversal of Streptozotocin-Induced Diabetes in Mice by Cellular Transduction with Recombinant Pancreatic Transcription Factor Pancreatic Duodenal Homeobox-1

Transient B-cell depletion and regulatory T-cells mediation in combination with adenovirus mediated IGF-1 prevents and reverses autoimmune diabetes in NOD mice

Reversal of Hyperglycemia by Protein Transduction of NeuroD in Vivo

Oral Administration of PDX1 Confers Protection Against Insulitis in the Non-Obese Diabetic (NOD) Mice.

Anti-CD20 Therapy Ameliorates Β Cell Function and Rebalances Th17/Treg Cells in NOD Mice

Prevention of Diabetes in NOD Mice by Administration of Dendritic Cells Deficient in Nuclear Transcription Factor-Kappab Activity.

Polyethylene Glycolated Recombinant TNF Receptor I Improves Insulitis and Reduces Incidence of Spontaneous and Cyclophosphamide-Accelerated Diabetes in Nonobese Diabetic Mice

Cooperation of Invariant NKT Cells and CD4+CD25+ T Regulatory Cells in Prevention of Autoimmune Diabetes in Non-Obese Diabetic Mice Treated with Alpha-Galactosylceramide.

Anti-hyperglycemic, antioxidant and anti-inflammatory effects of VIP and a VPAC1 agonist on streptozotocin-induced diabetic mice.

Effects of Oral Administration of Insulin and Glutamic Acid Decarboxylase on the Incidence of Diabetes Mellitus in Non-Obese Diabetic Mice

Induction of Active Tolerance and Involvement of Cd1d-Restricted Natural Killer T Cells in Anti-Cd3 F(Ab ')(2) Treatment-Reversed New-Onset Diabetes in Nonobese Diabetic Mice

Proposed mechanisms for oligonucleotide IMT504 induced diabetes reversion in a mouse model of immunodependent diabetes

The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice

Gene Therapy with Neurogenin3, Betacellulin and SOCS1 Reverses Diabetes in NOD Mice